Bristol-Myers Analyst Says 'Big 7' Pipeline Assets Hold $15B In Peak Sales Potential

Biopharma companies are among the most resilient among sectors during the coronavirus pandemic, and one large-cap biopharma has a slew of products in its pipeline that have blockbuster potential, according to BofA Securities. 

Brace For Bristol-Myers' ‘Big 7'

Bristol-Myers Squibb Co's BMY new product cycle consists of seven products across various higher-profile markets like hematology/oncology and immunology and inflammation, or I&I, analyst Geoff Meacham said in a recent note.

Following the Celgene deal, Bristol-Myers has one of the best portfolios across the biopharma industry, the analyst said.

BofA is cognizant of the loss of exclusivity related to Bristol-Myers' blood cancer drug Revlimid, which is expected to go off patent in 2022/2023. Yet investors aren't fully appreciating the upside potential from the portfolio, Meacham said. 

"We think the 'Big 7' new product cycle could exceed Revlimid's $12B franchise, and collectively we see potential for >$15B in peak sales."  

Most of the company's assets are already derisked and have an opportunity for a meaningful inflection point heading into near-term commercial launches, the analyst said. 

BofA highlighted the following seven pipeline assets: 

Inberic

  • Generic name: fedratinib
  • Drug Type: selective oral JAK2 inhibitor
  • Status: Approved in 2019; initial launch underway
  • Indication(s): treatment option for myelofibrosis patients who relapsed or are intolerant to Incyte Corporation's INCY Jakafi
  • BofA's Peak Potential Estimate: About $750 million

See also: The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive

Rebloyzl

  • Generic name: luspatercept
  • Drug Type: erythroid maturation agent
  • Status: initially approved in November 2019
  • Indication(s): treatment of anemia in adults with beta thalassemia and also anemia in adults with lower risk myelodysplastic syndrome
  • BofA's Peak Potential Estimate: over $2 billion in both indications

Zeposia

  • Generic name: ozanimod
  • Drug Type: oral S1P-r modulator
  • Status: approved in March 2020 for multiple sclerosis; launch scheduled for June 1
  • Indication(s): Apart from multiple sclerosis, it is being evaluated in late-stage studies for ulcerative colitis
  • BofA's Peak Potential Estimate: $3.5 billion for both indications

JCAR017

  • Generic name: liso-cel
  • Drug Type: lead chimeric antigen receptor T-cell product candidate
  • Status: in review, with a PDUFA date of mid-November
  • Indication(s): diffuse large B-cell lymphoma
  • BofA's Peak Potential Estimate: $2.5 billion for both indications

bb2121

  • Generic name: ide-cel
  • Drug Type: BCMA-targeted CAR-T therapy developed along with bluebird bio Inc BLUE Status: received a refuse-to-file letter from the FDA; refiling expected by July 2020 and approval likely in the first half of 2021 
  • Indication(s): relapsed/refractory multiple myeloma
  • BofA's Peak Potential Estimate: over $2.5 billion

CC-486

  • Generic name: CC-486
  • Drug Type: oral hypomethylating agent/oral formulation of Vidaza
  • Status: PDUFA date of early September
  • Indication(s): first-line acute myeloid leukemia
  • BofA's Peak Potential Estimate: $1.5 billion

TYKT

  • Generic name: BMS-'165
  • Drug Type: oral TYK2 or tyrosine kinase 2 inhibitor
  • Status: registrational data expected by year-end and potential filing by the first half of 2021 Indication(s): evaluated in various I&I indications, with a lead phase 3 program in psoriasis being the major value driver
  • BofA's Peak Potential Estimate: $2.5 billion

Bristol-Myers Rating & Price Target

BofA rates Bristol-Myers a Buy and $80 price target, suggesting roughly 30% upside from current levels.

BMY Price Action

At last check, Bristol-Myers shares were slipping by 0.58% to $59.98. 

Related Link: AstraZeneca Receives Over $1B In BARDA Funding For Coronavirus Vaccine

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechPrice TargetReiterationAnalyst RatingsTrading IdeasBofA SecuritiesGeoff Meacham
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!